Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NPI-0052 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| NPI-0052 | EXPERIMENTAL | Advanced Solid Tumor Malignancies and Refractory Lymphoma |
| Name | Type | Description |
|---|---|---|
| NPI-0052 | DRUG | NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation |
Inclusion Criteria: * Histologically-confirmed solid tumor malignancy (patients must be refractory to or demonstrate unacceptable toxicity towards effective therapy known to provide clinical benefit for their condition) OR refractory lymphoma (patients whose disease has progressed despite standard ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
NPI-0052 is an investigational small molecule being studied for the treatment of non-small cell lung cancer and other cancers. It is in Phase 1 clinical development and is not yet approved by the FDA.
NPI-0052 is being developed by Bristol-Myers Squibb Company, which is listed on the New York Stock Exchange under the ticker symbol BMY.
NPI-0052 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any use.
NPI-0052 has been studied in two completed Phase 1 trials. NCT00396864 enrolled 51 patients with advanced solid tumors or refractory lymphoma in the United States. NCT00667082 enrolled 22 patients with non-small cell lung cancer, pancreatic cancer, melanoma, lymphoma, or multiple myeloma in Australia.
NPI-0052 is also known as marizomib. It is a proteasome inhibitor being investigated for its anticancer activity.